Arrowhead Pharmaceuticals, Inc. $ARWR Shares Acquired by AlphaQuest LLC

AlphaQuest LLC raised its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 30,636.8% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 32,581 shares of the biotechnology company’s stock after acquiring an additional 32,475 shares during the quarter. AlphaQuest LLC’s holdings in Arrowhead Pharmaceuticals were worth $515,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in the business. GAMMA Investing LLC boosted its position in shares of Arrowhead Pharmaceuticals by 297.6% in the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,628 shares during the period. CWM LLC boosted its position in shares of Arrowhead Pharmaceuticals by 134.3% in the 1st quarter. CWM LLC now owns 4,401 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 2,523 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Arrowhead Pharmaceuticals by 29.5% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,335 shares of the biotechnology company’s stock valued at $84,000 after purchasing an additional 1,214 shares during the period. KBC Group NV boosted its position in shares of Arrowhead Pharmaceuticals by 40.8% in the 1st quarter. KBC Group NV now owns 7,356 shares of the biotechnology company’s stock valued at $94,000 after purchasing an additional 2,132 shares during the period. Finally, XTX Topco Ltd acquired a new stake in shares of Arrowhead Pharmaceuticals in the 1st quarter valued at about $133,000. 62.61% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Wall Street Zen cut Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, July 18th. Royal Bank Of Canada decreased their target price on Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an “outperform” rating for the company in a research report on Friday, August 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 8th. B. Riley raised Arrowhead Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 11th. Finally, TD Cowen raised Arrowhead Pharmaceuticals to a “strong-buy” rating in a research report on Monday, July 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Arrowhead Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $43.14.

Insider Activity

In other news, insider James C. Hamilton sold 20,000 shares of the stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. Following the completion of the transaction, the insider directly owned 212,122 shares of the company’s stock, valued at approximately $7,424,270. This represents a 8.62% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders sold 60,000 shares of company stock worth $1,725,000. Corporate insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals Stock Up 0.2%

Arrowhead Pharmaceuticals stock opened at $39.55 on Wednesday. The stock has a market capitalization of $5.47 billion, a price-to-earnings ratio of -30.90 and a beta of 1.13. The stock has a 50 day moving average of $31.37 and a two-hundred day moving average of $21.18. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $9.57 and a twelve month high of $40.48. The company has a current ratio of 4.87, a quick ratio of 4.87 and a debt-to-equity ratio of 0.39.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.32). The firm had revenue of $27.77 million during the quarter, compared to analyst estimates of $29.01 million. During the same period last year, the business posted ($1.38) earnings per share. As a group, research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.